Morgan Stanley Reaffirms “Overweight” Rating for Silence Therapeutics (NASDAQ:SLN)

Morgan Stanley reaffirmed their overweight rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report report published on Monday morning, Benzinga reports. Morgan Stanley currently has a $45.00 price target on the stock.

A number of other brokerages have also recently issued reports on SLN. Chardan Capital increased their target price on shares of Silence Therapeutics from $26.00 to $42.00 and gave the stock a buy rating in a research report on Thursday, March 14th. HC Wainwright reiterated a buy rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 15th. Finally, BMO Capital Markets assumed coverage on Silence Therapeutics in a research report on Wednesday, January 31st. They set an outperform rating and a $67.00 price target on the stock.

Silence Therapeutics Trading Down 1.1 %

NASDAQ SLN opened at $22.27 on Monday. The firm’s 50 day moving average price is $23.03 and its two-hundred day moving average price is $17.38. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.56 and a current ratio of 4.56. Silence Therapeutics has a twelve month low of $4.55 and a twelve month high of $27.72. The stock has a market cap of $666.54 million, a price-to-earnings ratio of -15.25 and a beta of 1.41.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.22). Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. The firm had revenue of $2.61 million during the quarter, compared to analyst estimates of $11.46 million. Equities analysts anticipate that Silence Therapeutics will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Silence Therapeutics in the fourth quarter worth about $110,000. Lynx1 Capital Management LP acquired a new position in Silence Therapeutics during the 3rd quarter worth approximately $2,315,000. Parkman Healthcare Partners LLC lifted its stake in Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the last quarter. Finally, Vivo Capital LLC acquired a new stake in Silence Therapeutics in the fourth quarter valued at approximately $8,862,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.